Prosecution Insights
Last updated: November 20, 2026
Application No. 17/786,708

POLYPEPTIDES, PROTEIN COMPLEXES AND METHOD FOR MAKING SAME

Final Rejection §103§112
Filed
Dec 20, 2022
Priority
Dec 20, 2019 — provisional 62/951,701 +1 more
Examiner
BRISTOL, LYNN ANNE
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kisoji Biotechnology Inc.
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
737 granted / 1163 resolved
+3.4% vs TC avg
Strong +40% interview lift
Without
With
+39.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
77 currently pending
Career history
1238
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
8.3%
-31.7% vs TC avg
§112
48.5%
+8.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1163 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims 1. Claims 1-153 are the original claims filed 6/17/2022. In the Preliminary Amendment of 12/202022, claims 2, 23, 57, 61, 63, 80, 91-92, 94, 96-98, 110, 112, 114, 121, 126 and 127 are amended, claims 3-21, 24-56, 58-60, 62, 64-79, 81- 90, 95, 100-109, 111, 113, 115-120, 122, 124-125 and 128-153 are canceled and new claims 154-161 are added. In the Reply of 12/16/2025, Claims 61, 112 and 127 are amended. In the Response of 8/17/2026, Claims 1-2 are amended, claims 22-23, 61, 63, 80, 98-99, 110, 112, 114, 121, 123, 126-127, and 154-161 are canceled, and new claims 162-167 are added. Claims 1-2, 57, 91-94, 96-97, and 162-167 are the pending claims. Applicant’s amendment of the claims raises new grounds for objection and rejection. The Office Action is final. Priority 2. USAN 17/786,708, filed 12/20/2022, is a National Stage entry of PCT/CA2020/ 051753, International Filing Date: 12/18/2020, PCT/CA2020 /051753 Claims Priority from Provisional Application 62/951,701, filed 12/20/2019. Information Disclosure Statement 3. As of 9/29/2026, a total of six (6) IDS are filed: 6/17/2022; 1/24/2023; 12/13/2023; 2/7/2025; 12/16/2025; and 8/17/2026. The corresponding initialed and dated 1449 form is considered and of record. Withdrawal of Objections Nucleotide and/or Amino Acid Sequence Disclosures 4. The replacement Sequence Listing in CFR filed 8/18/2026 is compliant pursuant to 37 CFR 1.821-1.825 and is of record. Specification 5. The objections to the disclosure because of informalities are withdrawn. Both clean substitute and marked-up copies of the specification are filed on 8/17/2026. a) The specification is amended to rectify the improper use of the terms ATCC, Tween, Tris, nanobody, DART, NOG MOUSE, AKTA PURE, which are trade names or marks used in commerce. b) The specification is amended to include sequence identifiers for peptides > 4 amino acids in length pursuant to 37 CFR 1.821-1.825. Claim Objections 6. The objections to Claims 1-2, 22-23, 57, 61, 63, 80, 91-94, 96-99, 110, 112, 114, 121, 123, and 155-159 because of informalities is moot for the canceled claims and withdrawn for the pending claims. a) Claims 1-2, 57, 61, 63, 80, 91-94, and 96-97 are amended in claim 1 to recite “A polypeptide comprising from an N- to C-terminus an amino acid sequence of formula b) Amend claims 22-23 are canceled. c) Claims 98, 110, 112, 114, 121, 123, 155-159 are canceled. d) Claim 99 is canceled. e) Claim 161 is canceled. f) Claim 2 is amended to recite “or CH3 mutations that form a heterodimer g) Claim 57 is now compliant for SEQ ID NOS: 27 and 29 in view of the replacement Sequence Listing in CFR filed 8/18/2026. h) Claims 1-2, 61, 98, 112 and 161 are amended to delete the use formula numbering. Withdrawal of Objections Claim Rejections - 35 USC § 112(b) 7. The rejection of Claims 63 and 156 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite is moot for the canceled claims. Withdrawal of Rejections Claim Rejections - 35 USC § 103 8. The rejection of Claim(s) Claims 1, 61, 63, 80, 91-94, and 96-97 under 35 U.S.C. 103 as being unpatentable over Wang (WO 2016192613); 1/24/2013; IDS 6/17/2022) is moot for the canceled claims and withdrawn for the pending claims. Wang does not teach or suggest a polypeptide having the formula (anti-tumor sdAb)-(Lb)-(DD)-(Lc)-(anti-CD3 sdAb)-(Ld)-(anti-PD-1 sdA) or (anti-tumor sdAb)-(Lb)-(DD)-(Lc)-(anti-PD-1 sdAb)-(Ld)-(anti-CD3 sdA), where Lb, Lc and Ld comprise one or more linkers, where the non-flexible Lc linkers are selected from the sequence of SEQ ID NO: 8-12 and 14. Wang does not teach or suggest the specific use of a non-flexible linker much less in a specific position for a single domain-comprising polypeptide as instant claimed. 9. The rejection of Claim(s) Claims 1-2 under 35 U.S.C. 103 as being unpatentable over Sasisekharan et al (USPN 11459405 B2; issued 2022-10-04; priority 2016-12-28) in view of DE KRUIF et al (AU 2018201326 B2; published 2020-02-06; filed 2018-02-23) is withdrawn. Neither Sasisekharan nor DE KRUIF teach or suggest a polypeptide having the formula (anti-tumor sdAb)-(Lb)-(DD)-(Lc)-(anti-CD3 sdAb)-(Ld)-(anti-PD-1 sdA) or (anti-tumor sdAb)-(Lb)-(DD)-(Lc)-(anti-PD-1 sdAb)-(Ld)-(anti-CD3 sdA), where Lb, Lc and Ld comprise one or more linkers, where the non-flexible Lc linkers are selected from the sequence of SEQ ID NO: 8-12 and 14. Neither Sasisekharan nor DE KRUIF teach or suggest the specific use of a non-flexible linker much less in a specific position (Lc) for a single domain-comprising polypeptide as instant claimed. 10. The rejection of Claim(s) Claims 22-23 under 35 U.S.C. 103 as being unpatentable over Sasisekharan et al (USPN 11459405 B2; issued 2022-10-04; priority 2016-12-28) in view of DE KRUIF et al (AU 2018201326 B2; published 2020-02-06; filed 2018-02-23) is moot for the canceled claims. 11. The rejection of Claim(s) Claims 98, 110, 112, 114, 121, 123, and 156-159 under 35 U.S.C. 103 as being unpatentable over Wang (WO 2016192613); 1/24/2013; IDS 6/17/2022) is moot for the canceled claims. 12. The rejection of Claim(s) 99 under 35 U.S.C. 103 as being unpatentable over Sasisekharan et al (USPN 11459405 B2; issued 2022-10-04; priority 2016-12-28) in view of DE KRUIF et al (AU 2018201326 B2; published 2020-02-06; filed 2018-02-23) is moot for the canceled claim. 13. The rejection of Claim(s) Claim 161 under 35 U.S.C. 103 as being unpatentable over Sasisekharan et al (USPN 11459405 B2; issued 2022-10-04; priority 2016-12-28) in view of DE KRUIF et al (AU 2018201326 B2; published 2020-02-06; filed 2018-02-23) is moot for the canceled claim. Rejections Maintained Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 14. The provisional rejection of Claims 1-2, 20240166739) is moot for the canceled claims and maintained for the pending claims. Applicants state the rejection remains provisional. The ref application was allowed on 6/17/2026, and the issue fee paid on 9/15/2026. Applicants allege the present claims recite non-flexible linkers. Response to Arguments The instant claims are drawn to a non-flexible linker. Ref claim 102 recites the linkers are “a rigid linker”. The specification of ‘579 teaches examples of a rigid linker such as: [0107] In some embodiments the rigid linker comprises multiple PA repeats as described herein. [0480] In some embodiments, the rigid linker is selected from PAPAPKA (SEQ ID NO:105); APAPAPAPAPKA (SEQ ID NO:106); APAPAPAPAPAPAPAPAPAPKA (SEQ ID NO:107); or combinations thereof. [0723] Specific exemplary and non-limiting embodiments of rigid linkers include those comprising of consisting of the amino acid sequence set forth in SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107 or SEQ ID NO:108. Instant claimed SEQ ID NO: 8 (PAPAPKA) corresponds to ref SEQ ID NO: 105; Instant claimed SEQ ID NO: 9 (APAPAPAPAPKA) corresponds to ref SEQ ID NO: 106; Instant claimed SEQ ID NO: 10 (APAPAPAPAPAPAPAPAPAPKA) corresponds to ref SEQ ID NO: 107. MPEP 804 (II)(B)(1) stating in part: The specification can be used as a dictionary to learn the meaning of a term in the claim. Toro Co. v. White Consol. Indus., Inc., 199 F.3d 1295, 1299, 53 USPQ2d 1065, 1067 (Fed. Cir. 1999). This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. 15. The provisional rejection of Claims 1-2 on the ground of nonstatutory double patenting as being unpatentable over claims 20-22 and 54-55 of copending Application No. 19/098,348 (reference application US 20250313638) is moot for the canceled claims and maintained for the pending claims. Applicants state the rejection remains provisional. The Office does not dispute the truth of the matter asserted. Applicants allege the present claims recite non-flexible linkers. Response to Arguments Ref claim 54 recites the position for Lc1 that corresponds to instant claimed (Lc) is a linker. The specification of ‘348 teaches examples of a rigid linker such as: [0089] In some embodiments, each of the one or more linkers is independently a flexible linker, a helical linker, or a rigid linker. [0638] Specific exemplary and non-limiting embodiments of rigid linkers include those comprising of consisting of the amino acid sequence set forth in SEQ ID NO:105, SEQ ID NO: 106, SEQ ID NO: 107 or SEQ ID NO:108. Instant claimed SEQ ID NO: 8 (PAPAPKA) corresponds to ref SEQ ID NO: 105; Instant claimed SEQ ID NO: 9 (APAPAPAPAPKA) corresponds to ref SEQ ID NO: 106; Instant claimed SEQ ID NO: 10 (APAPAPAPAPAPAPAPAPAPKA) corresponds to ref SEQ ID NO: 107. MPEP 804 (II)(B)(1) stating in part: The specification can be used as a dictionary to learn the meaning of a term in the claim. Toro Co. v. White Consol. Indus., Inc., 199 F.3d 1295, 1299, 53 USPQ2d 1065, 1067 (Fed. Cir. 1999). This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. New Grounds for Objection Claim Objections 16. Claims 1, 94, 162-163, and 166 are objected to because of the following informalities: a) Amend claim 1 to recite “the [list] group.” b) Amend claim 94 to recite “A recombinant cell.” c) Amend claim 162 to delete the duplicate recitation “PDL-1” for “PD-L1.” d) Amend claims 162-163 to recite “[has] specifically binds to.” e) Amend claim 166 to recite “[an] the amino acid sequence Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 17. Claim 57 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. a) Claim 57 recites “optional” language that is indefinite. It is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d). The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Written Description/ New Matter 18. Claim 162 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 162 recites the term “cWF” as a tumor target but which has no known meaning. It is unclear if what is intended are the CWF proteins that are core components or interacting partners of the Cdc5-associated (CWF) complex. (MPEP 706.03(m) states in part "New matter includes not only the addition of wholly unsupported subject matter but may also include adding specific percentages or compounds after a broader original disclosure, or even the omission of a step from a method. See MPEP § 608.04 to § 608.04(c). See In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976) and MPEP § 2163.05 for guidance in determining whether the addition of specific percentages or compounds after a broader original disclosure constitutes new matter.”) Written Description 19. Claims 1-2, 57, 91-94, 96-97, and 162-167 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 1-2, 57, 91-94, 96-97, and 162-167 are amended to explicitly recite the antigen binding domains for each of Aba, Abb and Abc is a single domain antibody (sdAb) directed to any tumor antigen, a CD3 and a PD-1, respectively. Except for claims 164-165, the sequence identify for the genus of sdAbs is not provided anywhere in the claims. Because applicants seek patent protection for all such polypeptides comprising infinite numbers of sdAbs for each of Aba, Abb and Abc, each genus must be adequately described. A description adequate to satisfy 35 U.S.C. § 112(a) must clearly allow persons of ordinary skill in the art to recognize that the inventor invented what is claimed (Ariad Pharms., Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010) (en banc) (citation omitted, alteration in original). The purpose of the written description requirement is to “ensure that the scope of the right to exclude, as set forth in the claims, does not overreach the scope of the inventor’s contribution to the field of art as described in the patent’s specification” (In re Katz Interactive Call Processing Patent Litig. 639 F.3d 1303, 1319 (Fed. Cir 2011). State of the Relevant Art By the time the invention was made, it was also well-established in the art that the formation of an intact antigen-binding surface on an antibody required the association of the complete heavy and light chain variable regions, each of which consists of three CDRs which provide the majority of the contact residues for the binding of the antibody to its target epitope (Almagro & Franssen, Frontiers in Bioscience, 13:1619-33 (2008) (PTO-892) (see Section 3 “Antibody Structure and the Antigen Binding Site” and Figure 1). While this overall architecture is shared among antibodies from a wide variety of sources (human, rat, mouse, rabbit), the structure each antibody uses to bind its particular epitope on an antigen is structurally distinct and is formed by a recombination event that results in high variability at the amino acid sequence level, even when the same antigen is bound (Edwards et al., J Mol Biol 334:103-118 (2003) (PTO-892); see also Marchalonis et al., Dev & Comp Immunol. 30:223-247 (2006) (PTO-892), summarized in Abstract and Conclusion. Overall, at the time the invention was made, the level of skill for preparing antibodies and then selecting those antibodies with desired functional properties was high. For example, it is generally the case that absent the fundamental structure provided for by all six CDRs of a parental antibody in the context of appropriate VH and VL framework sequences, a person of ordinary skill cannot visualize or otherwise predict, what an antibody with a particular set of functional properties would look like structurally. Moreover, persons of ordinary skill in the art have long since acknowledged that even minor changes in the amino acid sequences of the VH and VL, particularly in the CDRs, may dramatically affect antigen-binding function. Moreover, persons of ordinary skill in the art have long since acknowledged that even minor changes in the amino acid sequences of the VH and VL, particularly in the CDRs, may dramatically affect antigen-binding function. Lippow, for example, teaches that a single point mutation in the CDR of a parent antibody led to as much as an eightfold improvement in binding affinity in the resulting mutant (p. 1172, left col., lines 7-8 from end of first full paragraph and Table 1a) (Lippow et al., “Computational design of antibody-affinity improvement beyond in vivo maturation,” Nature Biotechnology, 25(10):1171-1176 (2007) (PTO-892). Sulea teaches that individual point mutations gave an improvement of one order of magnitude in binding affinity, which in turn, generated a 6-fold enhancement of efficacy at the cellular level (Abstract) (Sulea et al., “Application of Assisted Design of Antibody and Protein Therapeutics (ADAPT) improves efficacy of a Clostridium difficile toxin A single-domain antibody," Scientific Reports, 8(260):1-11 (2018) (PTO-892). Hasegawa et al. reports that a single amino acid substitution in the variable region was sufficient to alter the efficiency of biosynthesis and the variant antibody acquired stronger binding affinity to its antigen than the parent (Hasegawa et al., “Single amino acid substitution in LC-CDR1 induces Russell body phenotype that attenuates cellular protein synthesis through elF2a phosphorylation and thereby downregulates IgG secretion despite operational secretory pathway traffic,” MABS, VOL. 9, NO. 5, pp. 854-873 (2017) (PTO-892)). Altshuler teaches that generally, “CDR mutations should not involve residues that can play structural functions (form parts of the domain ‘internal core’, internal salt bridges, hydrogen bonds, etc.).” “Usually these are conservative residues, and any substitution of these residues causes decrease[s] in affinity” (Altshuler et al., “Generation of Recombinant Antibodies and Means for Increasing Their Affinity,” Biochemistry (Moscow), 75(13):1584-1605 (2010) at p. 1600, col. 1, para. 2, lines 1-5 (PTO-892). Accordingly, a person of ordinary skill in the art would have recognized that it was highly unpredictable that any of the CDRs or FRs could be modified to create an unlimited change in amino acids for both the CDRs and FRs, without increasing, eliminating, or in some way altering antigen binding. Are the disclosed species representative of the claimed genus? It is asserted that the disclosed species are not representative of the claimed genus because the claims encompass any sdAba, sdAbb and sdAbc. Where Lc is shown to be one of the claimed inflexible linkers (i.e., linker 2 in the Tables) comprised within a module is the following: PNG media_image1.png 606 988 media_image1.png Greyscale PNG media_image2.png 1282 1058 media_image2.png Greyscale PNG media_image3.png 463 970 media_image3.png Greyscale PNG media_image4.png 173 978 media_image4.png Greyscale PNG media_image5.png 174 1004 media_image5.png Greyscale The genus of all possible polypeptides encompassed by the claimed polypeptide would be structurally distinct but unpredictable whether the structure/function correlation was met for binding to the genus of tumor antigens much less any CD3 or PD-1. Neither the specification nor the prior art provides guidance as to what structural changes can be made to the parent sequences and still predictably arrive at an antibody that binds podoplanin. The disclosed species therefore do not represent the claimed genus. Has Applicant provided a common structure sufficient to visualize the genus? Applicants have not provided a common structure sufficient to visualize the genus of all possible functional variants for the claimed polypeptides of the invention. One of ordinary skill in the art would not have known which sdAb would maintain selectivity and affinity, or which could be conservatively changed much less which could not be changed at all. Single domain antibodies are still not understood well enough to allow researchers to predict with certainty what modifications can be made to a primary antibody sequence such that binding is maintained. “[T]he major test of understanding is whether the changes associated with antibody maturation can be predicted with any reasonable accuracy, and whether there is sufficient information for developing therapeutic antibodies,” Vajda et al., “Progress toward improved understanding of antibody maturation,” Current Opinion in Structural Biology, 67 pp. 226-231 (2021 (PTO 892)) at p. 226, col. 2, lines 20-24. As recently as 2020, researches were still speculating as to how to reliably identify further putative binders from antibody sequence data, see, e.g., Marks et al., “How repertoire data are changing antibody science,” J. Biol. Chem. 295(29) 9823-9837 (2020 (PTO 892)), acknowledging that “there is a vast amount of the antibody sequence space that remains unknown,” p. 9831, col. 2, para. 2. Computational and machine learning approaches for sequence-based prediction of paratope-epitope interactions are accumulating, but “it remains unclear whether antibody-antigen binding is predictable” (Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021 at p. 2, col. 2, para. 2 (PTO 892)). The current state of the art continues to work toward finding an effective and efficient prediction tool for reliably assigning antibody structure based on known target epitopes. See e.g., Lo et al., “Conformational epitope matching and prediction based on protein surface spiral features,” BMC Genomics volume 22, Article number: 116 (2021 (PTO 892)) (disclosing new algorithms that calculate physicochemical properties, such as polarity, charge or the secondary structure of residues within the targeted protein sequences, and then applying quantitative matrix analyses or machine-learning algorithms to predict linear and conformational epitopes). It is asserted that neither the specification nor the state of art at the time of filing disclosed structural features common to the members of the genus of polypeptides for reliably assigning different antibody structures based on sequence data for limited constructs shown in the specification, which would support the premise that the inventors possessed the full scope of the claimed invention. Conclusion 20. No claims are allowed. 21. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. 22. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LYNN A. BRISTOL whose telephone number is (571)272-6883. The examiner can normally be reached Mon-Fri 9 AM-5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Julie can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LYNN A BRISTOL/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Dec 20, 2022
Application Filed
Mar 17, 2026
Non-Final Rejection mailed — §103, §112
Aug 17, 2026
Response Filed
Oct 02, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780949
ANTI-CLAUDIN 18.2 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
3y 9m to grant Granted Nov 03, 2026
Patent 12723105
MONOSPECIFIC AND MULTI-SPECIFIC ANTIBODIES
4y 5m to grant Granted Sep 01, 2026
Patent 12723106
PROTEASE-PROCESSED MOLECULES
4y 0m to grant Granted Sep 01, 2026
Patent 12723083
ANTI-CD3/ANTI-CD28 BISPECIFIC ANTIGEN BINDING MOLECULES
3y 8m to grant Granted Sep 01, 2026
Patent 12708667
COMPOSITIONS AND METHODS CONCERNING COMBINATIONS OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER
5y 6m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+39.7%)
3y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1163 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month